已收盤 11-20 16:00:00 美东时间
-0.091
-9.01%
今日重点评级关注:瑞银:维持Liberty Media"中性"评级,目标价从110美元升至1116美元;杰富瑞:维持伊诺维奥制药"买入"评级,目标价从3美元升至8美元
11-09 14:00
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $3.5 to $3.
11-06 22:53
Fate Therapeutics ( ($FATE) ) has provided an announcement. On November 5, 2026...
11-06 05:47
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 7.41 percent increase over losses of $(0.27) per share from the same period last year.
11-05 20:37
Fate Therapeutics granted stock options and RSUs to newly-hired non-executive employees on November 2, 2026, under its equity plan. The options allow purchase of 300,000 shares at $2.01 per share, vesting over four years. RSUs for 87,000 shares also vest over four years. Both grants were approved by the Compensation Committee and align with Nasdaq Listing Rule 5635(c)(4). The Company focuses on iPSC-derived immunotherapies for cancer and autoimmu...
11-03 21:05
今日重点评级关注:富瑞:维持ArriVent BioPharma"买入"评级,目标价从18美元升至30美元;古根海姆:维持第一太阳能"买入"评级,目标价从282美元升至299美元
10-28 12:30
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in proteinuria Encouraging safety profile with no dose-limiting toxic...
10-26 19:02
Fate Therapeutics' FT819, an off-the-shelf CAR T-cell therapy, demonstrated 100% renal response in active LN patients with a 50% reduction in proteinuria at Month 6. Safety data showed no dose-limiting toxicities, high-grade CRS, ICANS, GvHD, or IEC-HS, supporting outpatient administration. The therapy also improved lupus disease activity and fatigue scores, with B-cell depletion and reconstitution observed. These results support the ongoing Phas...
10-26 11:00
Entera Bio Ltd. announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. With over 35 years of experience in global commercial leadership, Hamill joins Entera as it advances its late-stage clinical trials and prepares for the commercialization of EB613, an oral therapy for osteoporosis. Hamill previously served at Gilead Sciences and Amgen, leading multi-billion dollar franchises. Her expertise is expected ...
10-06 12:00
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to fund advancing clinical trials for stem cell and gene therapies that have the poten...
09-25 19:07